Telix Pharmaceuticals (TLX) Receivables - Other (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Receivables - Other for 3 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Receivables - Other fell 24.37% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 24.37% year-over-year, with the annual reading at $1.3 million for FY2025, 27.22% down from the prior year.
  • Receivables - Other for Q4 2025 was $1.3 million at Telix Pharmaceuticals, down from $1.7 million in the prior quarter.
  • The five-year high for Receivables - Other was $1.7 million in Q4 2024, with the low at $1.3 million in Q4 2025.
  • Average Receivables - Other over 3 years is $1.5 million, with a median of $1.5 million recorded in 2023.
  • The sharpest move saw Receivables - Other grew 10.53% in 2024, then decreased 24.37% in 2025.
  • Over 3 years, Receivables - Other stood at $1.5 million in 2023, then grew by 10.53% to $1.7 million in 2024, then fell by 24.37% to $1.3 million in 2025.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $1.3 million, $1.7 million, and $1.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.